Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com
April 7, 2022 / 5:30-7:30pm PT

Join us at ASBrS 2022 for a symposium

Speakers

I agree to be contacted by a representative of Exact Sciences about the Oncotype DX test and accept the Terms & Conditions. For more information about our privacy practices, please read our Privacy Policy.